Comparative Pharmacology
Head-to-head clinical analysis: CLOPRA versus COMPRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOPRA versus COMPRO.
CLOPRA vs COMPRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clopra (metoclopramide) is a dopamine D2 receptor antagonist and a 5-HT4 receptor agonist, enhancing gastrointestinal motility and having antiemetic effects via central and peripheral actions.
Prochlorperazine is a phenothiazine antipsychotic that primarily acts as a dopamine D2 receptor antagonist, with additional antagonism at D3, 5-HT2A, alpha1-adrenergic, and histamine H1 receptors. It also has antiemetic effects via D2 blockade in the chemoreceptor trigger zone.
Clopra (metoclopramide) 10 mg orally or intramuscularly 30 minutes before meals and at bedtime; maximum 30 mg/day. For intravenous administration, give 10 mg over 1-2 minutes.
5 to 10 mg intramuscularly every 3 to 4 hours as needed; or 5 to 10 mg intravenously at a rate not exceeding 5 mg per minute; or 10 mg orally every 6 to 8 hours; maximum daily dose 40 mg.
None Documented
None Documented
Clinical Note
moderateMetoclopramide + Haloperidol
"The risk or severity of adverse effects can be increased when Metoclopramide is combined with Haloperidol."
Clinical Note
moderateMetoclopramide + Quinagolide
"The therapeutic efficacy of Quinagolide can be decreased when used in combination with Metoclopramide."
Clinical Note
moderateMetoclopramide + Cyclosporine
"Metoclopramide can cause an increase in the absorption of Cyclosporine resulting in an increased serum concentration and potentially a worsening of adverse effects."
Clinical Note
moderateTerminal elimination half-life 6-8 hours (prolonged in renal impairment; up to 20 hours in severe CKD)
Terminal elimination half-life: 4-6 hours in adults (prolonged in hepatic impairment, cirrhosis up to 10-12 hours; neonates up to 24 hours).
Renal (50-70% as unchanged drug and metabolites); fecal (20-30%); biliary (minor ~5%)
Renal: 70-80% as glucuronide and sulfate conjugates; biliary/fecal: <10% unchanged; <5% as unchanged drug in urine.
Category C
Category C
Antiemetic/Prokinetic Agent
Antiemetic
Metoclopramide + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Metoclopramide."